Current treatment options for clinical stage I seminoma

World Journal of Urology

Volumn 27, Issue 4, 2009, Pages 427-432

  Stephenson, Andrew J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy, adjuvant; Neoplasm recurrence, local; Neoplasms, germ cell and embryonal; Radiotherapy, adjuvant; Retroperitoneum; Seminoma; Testicular neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; HEALTH SURVEY; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SEMINOMA; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; POPULATION SURVEILLANCE; RADIOTHERAPY, ADJUVANT; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 68549120950     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0409-x     Document Type: Article

References (29)

1. Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ et al (1999) Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17(4):1146
2. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF, Moore M et al (1995) Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 13(9):2255-2262
3. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H et al (2005) Second cancers among 40, 576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97(18):1354-1365
4. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG et al (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25(28):4370-4378. doi: 10.1200/JCO.2006.10.5296
5. Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22(4):640-647. doi: 10.1200/ JCO.2004.05.205
6. Sharp DS, Carver BS, Eggener SE, Motzer RJ, Bosl GJ, Sheinfeld J (2008) Clinical outcome of patients managed for late relapse of germ cell tumor. J Clin Oncol 26:5524-5529
7. Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O et al (2005) Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J Urol 173(3):824-829. doi: 10.1097/ 01.ju.0000154013.96349.36
8. Fossa SD, Aass N, Kaalhus O (1989) Radiotherapy for testicular seminoma stage I: Treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16(2):383-388
9. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R et al (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 90(12):2305-2311
10. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A et al (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6):1200-1208. doi: 10.1200/ JCO.2005.08.003
11. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial. Lancet 366(9482):293-300. doi: 10.1016/S0140-6736(05)66984-X
12. Warde P, Gospodarowicz M, Panzarella T, Guiliani M, Tew-George E, Milosevic M, et al (2005) Outcome in stage I seminoma managed by radiation therapy and surveillance. J Urol 4(Suppl):196, abstract 719
13. Brenner DJ, Hall EJ (2007) Computed tomography - an increasing source of radiation exposure. N Engl J Med 357(22):2277-2284. doi: 10.1056/ NEJMra072149
14. Chung P, Parker C, Panzarella T, Gospodarowicz MK, Jewett S, Milosevic MF et al (2002) Surveillance in stage I testicular seminoma - risk of late relapse. Can J Urol 9(5):1637-1640
15. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65(5):775-778
16. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL, Pedersen M et al (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 29A(14):1931-1934. doi: 10.1016/ 0959-8049(93)90446-M
17. Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. Apmis 111(1):76-83 discussion 5
18. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N et al (2005) Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61(3):736-740. doi: 10.1016/ j.ijrobp.2004.06.209
19. Aparicio J, Garcia del Muro X, Maroto P, Paz-Ares L, Alba E, Saenz A et al (2003) Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14(6):867-872. doi: 10.1093/annonc/mdg241
20. Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A et al (2005) Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23(34):8717-8723. doi: 10.1200/JCO.2005.01.9810
21. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA et al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 - the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25(11):1310-1315. doi: 10.1200/JCO.2006.08.4889
22. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 20(22):4448-4452. doi: 10.1200/JCO.2002.01.038
23. Oliver RT, Edmonds PM, Ong JY, Ostrowski MJ, Jackson AW, Baille-Johnson H et al (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29(1):3-8
24. Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H (2000) Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 55(1):102-106. doi: 10.1016/S0090-4295(99)00376-3
25. Steiner H, Holtl L, Wirtenberger W, Berger AP, Bartsch G, Hobisch A (2002) Long-term experience with carboplatin monotherapy for clinical stage I seminoma: A retrospective single-center study. Urology 60(2):324-328. doi: 10.1016/S0090-4295(02)01708-9
26. Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U et al (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19(1):101-104
27. Oliver RT, Mead GM, Fogarty PJ, Stenning SP (2008) Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26(15S):5S, abstract 1. doi: 10.1200/JCO.2008.16.7874
28. Calvert AH, Egorin MJ (2002) Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 38(1):11-16. doi: 10.1016/S0959-8049(01)00340-9
29. Mead GM, Fossa SD, Oliver RT, Fogarty PJ, Pollock P, Stenning SP (2008) Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials. J Clin Oncol 26(15S):255s abstract 5020